Lisata Therapeutics and Valo Therapeutics Collaborative Research
Lisata Therapeutics, Inc. (NASDAQ: LSTA), recognized for its commitment to developing groundbreaking therapies aimed at advanced solid tumors and other critical health issues, has formed a noteworthy preclinical research partnership with Valo Therapeutics Oy (ValoTx), a pioneer in adaptable immunotherapies for cancer. This collaboration centers on evaluating the integration of Lisata's innovative candidate, certepetide, with ValoTx's unique PeptiCRAd technology, alongside a checkpoint inhibitor, particularly in melanoma mouse models.
Kristen K. Buck, M.D., Executive Vice President of Research and Development at Lisata, expressed enthusiasm about the collaboration by stating, "Building on past preclinical findings that indicate the beneficial effects of certepetide in tandem with various immunotherapies, we are eager to explore its additional advantages when combined with ValoTx's PeptiCRAd. The functional synergy between these treatments, particularly certepetide's role in transforming the tumor microenvironment for enhanced responsiveness, suggests promising improvements in patient care against the backdrop of existing challenges like resistance and recurrence in melanoma therapies."
Breakthroughs in Innovative Cancer Treatments
Continuing the conversation, Sari Pesonen, Ph.D., the CEO of ValoTx, remarked, "This collaboration with Lisata Therapeutics represents a thrilling opportunity to push the boundaries of cancer treatment. The fusion of our proprietary PeptiCRAd platform with Lisata's advanced certepetide tech aims to develop groundbreaking immunotherapy solutions. We are committed to bringing transformative treatments to those who need them most, translating our preclinical successes into impactful therapies for patients struggling with cancer."
The Urgent Need for Effective Melanoma Therapies
Melanoma stands as a severe form of skin cancer, recognized for its high mortality rate. According to global health statistics, melanoma accounts for an alarming number of cancer-related fatalities every year, emphasizing the critical need for more effective treatment methods. While current therapies involving checkpoint inhibitors achieve modest response rates of 35-60%, there remains a substantial gap in effective options, particularly for those with advanced or metastatic forms of the disease.
Certepetide: A Promising Investigational Drug
Certepetide, Lisata's investigational drug, is characterized by its ability to activate the C-end rule active transport mechanism selectively within tumors. This innovative approach allows for the enhanced delivery of anti-cancer agents directly to malignancies. Moreover, it has shown promise in reshaping the tumor microenvironment, lessening its immune suppression and curtailing metastasis. Extensive preliminary data indicates that certepetide significantly improves the delivery and impact of existing and new cancer treatments, including chemotherapies and immunotherapies.
About the Technologies at Play
ValoTx’s PeptiCRAd Platform
The PeptiCRAd platform represents a cutting-edge leap in immunotherapy, utilizing engineered, replication-competent adenoviruses designed for optimal activation of the tumor microenvironment. Its flagship candidate, PeptiCRAd-1, is an innovative design that encodes significant immune-enhancing proteins delivered directly to the tumor area. This technology uniquely allows the incorporation of multiple tumor-specific antigens, triggering a robust immune response against a range of cancer markers. The adaptability of PeptiCRAd ensures precise treatments tailored to the diverse antigen profiles found in solid tumors, a crucial advantage over standard immunotherapies.
Lisata’s Commitment to Cancer Care
Lisata Therapeutics is focused on not just innovating cancer treatments but also ensuring their successful commercialization. Their flagship product, certepetide, is especially noteworthy. It aims to leverage strategic partnerships and clinical trials to pave the way for breakthroughs in oncology. With a solid financial outlook, Lisata anticipates advancing its initiatives into 2026, showcasing a strong commitment to enhancing patient lives through innovative therapeutic solutions.
Frequently Asked Questions
What is the goal of the research collaboration between Lisata and Valo?
The collaboration aims to explore the potential benefits of combining Lisata's certepetide with ValoTx's PeptiCRAd platform for improved cancer treatments.
What are certetepide's distinctive features?
Certepetide is designed to improve the delivery of anti-cancer agents by enhancing tumor penetration and modifying the tumor microenvironment to enhance immune response.
Why is melanoma a focus for these therapies?
Melanoma is associated with high mortality rates and significant unmet medical need, making it a priority for innovative treatment strategies.
What advancements does PeptiCRAd technology provide?
PeptiCRAd offers a customizable approach to activate the tumor microenvironment and can target multiple tumor antigens, enhancing immune responses to a variety of cancers.
How is Lisata Therapeutics positioned for the future?
Lisata is poised for growth, with strategic partnerships and ongoing clinical trials expected to drive advancements in cancer therapies well into the coming years.
